SYNC

Across TCGA pan-cancer cohorts, SYNC mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SYNC data layer compared with 26 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher SYNC mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated SYNC expression acts as an unfavorable survival marker.

LUAD, PDAC, and LSCC are the cancer types where SYNC mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	II,III,IV	0.757	0.949	.002	14	view →
PDAC	DFS	Quartile	III,IV	0.337	0.909	.013	7	view →
LSCC	DFS	Median	II,III,IV	0.829	1.000	.003	6	view →
GBM	DFS	Median	All	0.669	0.762	.042	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

SYNC–LUAD (DFS)

Open the LUAD breakdown →